Tamoxifen and chemotherapy for axillary node-negative, estrogen receptor-negative breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-23.
about
NSABP breast cancer clinical trials: recent results and future directionsProgress in adjuvant chemotherapy for breast cancer: an overviewCurrent treatment of early breast cancer: adjuvant and neoadjuvant therapyA randomized placebo-controlled study of tamoxifen after adjuvant chemotherapy in premenopausal women with early breast cancer (National Cancer Institute of Canada--Clinical Trials Group Trial, MA.12)American Society of Clinical Oncology clinical practice guideline: update on adjuvant endocrine therapy for women with hormone receptor-positive breast cancer.Growth factor receptor-bound protein-7 (Grb7) as a prognostic marker and therapeutic target in breast cancer.Age and survival estimates in patients who have node-negative T1ab breast cancer by breast cancer subtypeAdjuvant chemotherapy in breast cancer: To use or not to use, the anthracyclinesTamoxifen plus tegafur-uracil (TUFT) versus tamoxifen plus Adriamycin (doxorubicin) and cyclophosphamide (ACT) as adjuvant therapy to treat node-positive premenopausal breast cancer (PreMBC): results of Japan Clinical Oncology Group Study 9404Risk of hospitalization according to chemotherapy regimen in early-stage breast cancer.The expanding role of epirubicin in the treatment of breast cancer.Toward optimal screening strategies for older women. Costs, benefits, and harms of breast cancer screening by age, biology, and health status.Adjuvant chemotherapy in older women with early-stage breast cancer.EZH2 and ALDH-1 mark breast epithelium at risk for breast cancer development.Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trialsThe promise of methylation on beads for cancer detection and treatment.Potentiation of mammary cancer inhibition by combination of antagonists of growth hormone-releasing hormone with docetaxel.Immunohistochemical subtypes predict the clinical outcome in high-risk node-negative breast cancer patients treated with adjuvant FEC regimen: results of a single-center retrospective study.Recent advances in adjuvant systemic treatment for breast cancer: all systems go!The Globalization of Cooperative Groups.Evaluation of the Survival Benefit of Different Chemotherapy Regimens in Patients with T1-2N0 Triple-Negative Breast Cancer.Non-surgical therapy and radiologic assessment of stage I breast cancer treatment with novel enzyme-targeting radiosensitization: Kochi Oxydol-Radiation Therapy for Unresectable Carcinomas, type II (KORTUC II)Time-Varying Effects of Breast Cancer Adjuvant Systemic TherapySurvival benefit of tamoxifen in estrogen receptor-negative and progesterone receptor-positive low grade breast cancer patients.Enhanced cytotoxicity in triple-negative and estrogen receptor‑positive breast adenocarcinoma cells due to inhibition of the transient receptor potential melastatin-2 channel.A randomised factorial trial of sequential doxorubicin and CMF vs CMF and chemotherapy alone vs chemotherapy followed by goserelin plus tamoxifen as adjuvant treatment of node-positive breast cancerPrognosis after ipsilateral breast tumor recurrence and locoregional recurrences in patients treated by breast-conserving therapy in five National Surgical Adjuvant Breast and Bowel Project protocols of node-negative breast cancerRecent advances in systemic therapy: advances in adjuvant systemic chemotherapy of early breast cancer.Hazard of recurrence and adjuvant treatment effects over time in lymph node-negative breast cancer.Adjuvant hormonal therapy use among insured, low-income women with breast cancer.Physician-related facilitators and barriers to patient involvement in treatment decision making in early stage breast cancer: perspectives of physicians and patients.Role of trastuzumab in the adjuvant treatment of HER2-positive early breast cancer.Adherence to adjuvant endocrine therapy in estrogen receptor-positive breast cancer patients with regular follow-up.Adjuvant chemotherapy for older adults with breast cancer: making the standard a standard.Targeting the cancer-associated fibroblasts as a treatment in triple-negative breast cancer.Quality-of-life measurement in randomized clinical trials in breast cancer: an updated systematic review (2001-2009).CMF revisited in the 21st century.Chemotherapy regimens in early breast cancer: major controversies and future outlook.Quality evaluation of medical care for breast cancer in Japan.Expression of Aurora A (but not Aurora B) is predictive of survival in breast cancer.
P2860
Q24520573-F2653F04-5432-40F1-85C1-FB47BC458C5DQ26798078-32EF0BE2-94DE-4CDE-85EA-46785AC82647Q27011658-9CDE8484-8DA5-4D77-A43F-3DE71046F1D0Q33618145-E7082B46-04C8-4115-BEC4-6341CF44206CQ33631047-7A55FF15-51E4-4C60-9207-7D764EAE46DCQ33676758-6A1649B0-B89F-439B-86FB-81BC091964D8Q33922150-494EC496-1432-4354-961D-4E8706CD683DQ34023749-D55EE59F-6A94-45A8-9F64-83C70C51DFD4Q34085163-CA7E678B-EE9E-4348-8D5A-1DA989E9D17DQ34184798-AADDFA05-E9EE-4E89-A87D-67AEB88FF4FAQ34608626-19CE68F3-343D-4E87-A4EA-323649BDA196Q34723307-7EA001ED-3D0F-4779-88DD-2618780F968DQ34858284-336A3B43-3CAD-4DA5-9BD5-ACFA100B9CEEQ35019505-CF1C1DA3-EB35-4A0D-AC33-34EA2734C155Q35186747-8437183A-1D41-43C5-A82C-847FEE025360Q35594733-B8513AC8-CE70-43C9-AD01-011521484F88Q35629436-5430E55E-D3BE-44DE-BEE5-5929A1751A64Q35807180-0BE20FC8-AE35-4DE1-9B42-C1459FF83B85Q36089069-4A2AA6EF-5540-4666-962D-728F1EF0BF0DQ36119749-66F619C1-016B-4BFA-96CC-5FD6323339B6Q36145737-BB2CF49D-CBFE-4B0E-AE96-51F84AD28A3EQ36244111-38BBA91C-DBB2-47E0-8059-9CB6B7A2A1A2Q36255577-48250883-792A-43CD-8D6E-8078E01C6479Q36310191-60356373-9E08-462D-A8B4-8984A79F347AQ36528114-EE0DF652-130B-4674-ABE5-C16B0C141DC0Q36617051-06E0E48F-99CE-412B-B3C6-FD7F71425A57Q37198977-603772A1-C308-408D-B967-BC4AFD6C5764Q37208730-CAC3F37D-E3EB-492A-811F-4922664878FFQ37263046-63E559E9-18CA-4054-9B08-703AF4957632Q37280714-0E3229C2-C732-4821-8398-22531FFC0A0FQ37332980-A70E8F3E-A48F-48CA-B8E4-AB99B3CD7A9BQ37401837-E75E51BE-E209-404D-A217-06AE9D238C10Q37538355-90C7038E-3F85-4C15-A3A8-FB8DD5C436B3Q37585297-3F4B36A3-9D08-40C5-B6E3-93B0D1E04E7BQ37686160-B58205BC-88FF-43E5-BC35-FDF36FA32C1AQ37827010-0E94A507-41A3-48E4-B625-AE6B787802D1Q37895805-D671DF7F-E67C-4FB1-A619-99972E3B04C1Q38081243-367DC4D9-DA55-44FC-AFCC-F5B0528215C3Q38669506-1130900D-ACE6-4EE9-B882-65B6BF1BD54DQ39961166-D63766A0-B2DE-4B1F-A9C9-1AC905B9E2DD
P2860
Tamoxifen and chemotherapy for axillary node-negative, estrogen receptor-negative breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-23.
description
2001 nî lūn-bûn
@nan
2001 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Tamoxifen and chemotherapy for ...... Breast and Bowel Project B-23.
@ast
Tamoxifen and chemotherapy for ...... Breast and Bowel Project B-23.
@en
type
label
Tamoxifen and chemotherapy for ...... Breast and Bowel Project B-23.
@ast
Tamoxifen and chemotherapy for ...... Breast and Bowel Project B-23.
@en
prefLabel
Tamoxifen and chemotherapy for ...... Breast and Bowel Project B-23.
@ast
Tamoxifen and chemotherapy for ...... Breast and Bowel Project B-23.
@en
P2093
P1476
Tamoxifen and chemotherapy for ...... Breast and Bowel Project B-23.
@en
P2093
C G Kardinal
D L Wickerham
E H Romond
E R Fisher
E Tan-Chiu
H R Shibata
J N Atkins
N Abramson
N V Dimitrov
P304
P356
10.1200/JCO.2001.19.4.931
P407
P577
2001-02-01T00:00:00Z